Drugs / Ferricarboxymaltose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT01288651 | Jan 2011 → Dec 2012 | idiopathic pulmonary arterial hypertension | Amsterdam UMC, location VUmc | Unknown | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00978575 Comparator | Apr 2010 → Jan 2013 | anemia | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ferricarboxymaltose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00978575 ↗ |
| Known as | Ferinject | “Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration.” NCT01288651 ↗ |
| Route | Intravenous | “ferricarboxymaltose intravenous” NCT00978575 ↗ |